Information Provided By:
Fly News Breaks for July 17, 2017
RPRX
Jul 17, 2017 | 13:45 EDT
Ladenburg Thalmann analyst Matt Kaplan terminated coverage of Repros Therapeutics saying the potential viability of the company's lead program, Proellex, in patients with uterine fibroids or endometriosis, is uncertain. Repros is down 33% to 38.5c after receiving feedback from the FDA indicating the Proellex program will remain on partial clinical hold.
News For RPRX From the Last 2 Days
There are no results for your query RPRX